Neurons are specialized cells with a high metabolic demand to fulfill their function, survive or keep a healthy half-life. In this sense, the anabolism and catabolism of proteins and lipids could be associated to different neurodegenerative diseases. At the 2022 annual meeting of the Society for Neuroscience, scientists reported the latest discoveries on neuron metabolic needs at a session on 'Powering Thoughts: The Regulation of Neuronal Energy Metabolism and Mitochondria.'
New and updated preclinical data presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting in Boston, by: Ankyra, Antengene, Artiva, Asher, Bluesphere, Catamaran, Cellectis, Century, Cytoimmune, Domain, Iconovir, Immunitas, Imugene, Imvax, Triumvira Immunologics, Tscan, Umoja.
Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent inhibitor of phosphoinositide 3-kinase α (PI3Kα), TOS-358, which is being developed for the treatment of cancer.
Researchers from Black Diamond Therapeutics Inc. presented the discovery and preclinical characterization of a novel brain-penetrant BRAF class I/II/III mutation inhibitor, BDTX-4933.
Increased expression and elevated levels of matrix metalloproteinase-2 (MMP-2) and MMP-9 play a role in impaired cardiac function. These MMPs make for essential targets in the treatment of heart failure, specifically heart failure with preserved ejection fraction (HFpEF).
Researchers from Aligos Therapeutics Inc. have described the discovery of novel liver-targeted oral PD-L1 small-molecule inhibitors for the treatment of chronic hepatitis B and liver cancers.
Calcium/calmodulin-dependent protein kinase II (CaMKII) is involved in the regulation of calcium and its hyperactivation can lead to cardiac issues, particularly with rhythm and contraction.
CD39 has an essential role in converting extracellular adenosine triphosphate (ATP; pro-inflammatory) into adenosine monophosphate (AMP; anti-inflammatory). Preventing the action of CD39 in the tumor microenvironment would increase levels of ATP, causing myeloid cell activation and improvement of tumor control.
Stimulating the brain via implanted electrodes is used to treat both movement disorders such as Parkinson’s disease, and some psychiatric conditions such as obsessive compulsive disorder. But researchers are also working on ways to make such implanted electrodes listen instead of talk – and translate neuronal signals for people that have lost the ability speak, or the ability to move. At the Neurophysiology: Decoding and Neural Processing II session of the 2022 Annual Meeting of the Society for Neuroscience in San Diego, researchers from the Wyss Center for Bio and Neuroengineering (Switzerland) presented a device implanted in the brain that allowed restoration of movement and speech.
Pegylated interferon-α (PegIFNα) is a treatment option for chronic hepatitis B (CHB) patients, but it often has undesirable side effects and not all patients respond to treatment. Tripartite motif-containing protein 26 (TRIM26) has been reported to have an impact on hepatitis C virus replication; researchers aimed to investigate the role of TRIM26 in CHB as well as its potential impact on response to PegIFNα in two cohorts of patients with CHB (N=945) treated for 48 weeks with a follow-up period of 24 weeks.
RSS
